secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950103-24-012144
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI closes $316.25M convertible notes offering; upsizes due to demand
---------------------------------------------------------------------

- $316.25M aggregate principal of 2.25% convertible senior notes due 2029 issued; upsized from $250M initial offering.
- Net proceeds of ~$306.8M; $40.6M used for capped call transactions to reduce potential dilution.
- Remainder plus cash on hand used to repay ~$292.5M outstanding under existing senior secured credit agreement.
- Entered new $400M credit facility ($325M delayed draw term loan + $75M revolver) to partially finance pending Alimera Sciences merger.
- Capped call transactions cap price $114.02/share, a 100% premium over $57.01 closing price on pricing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000095010324012144/0000950103-24-012144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000095010324012144/dp216536_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-012144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer